Objective-We tested the hypothesis of a role for the calcium-dependent protease calpain in the endothelial dysfunction induced by hyperglycemic activation of protein kinase C (PKC). Methods and Results-Chronic hyperglycemia with insulin deficiency (type 1 diabetes) was induced in rats by streptozotocin. Total PKC and calpain activities, along with activity and expression level of the 2 endothelial-expressed calpains isoforms,and m-calpain, were measured in vascular tissue homogenates by enzymatic assays and Western blot analysis, respectively. Intravital microscopy was used to measure and correlate leukocyte-endothelium interactions with calpain activity in the microcirculation. Expression levels and endothelial localization of the inflammatory adhesion molecule intercellular adhesion molecule-1 were studied by Western blot analysis and immunofluorescence, respectively. The mechanistic role of hyperglycemia alone in the process of PKC-induced calpain activation and actions was also investigated. We found that in the type 1 diabetic vasculature, PKC selectively upregulates the activity of the -calpain isoform. Mechanistic studies confirmed a role for hyperglycemia and PKC␤ in this process. The functional implications of PKC-induced calpain activation were upregulation of endothelial expressed intercellular adhesion molecule-1 and leukocyte-endothelium interactions. Conclusion-Our results uncover the role of -calpain in the endothelial dysfunction of PKC. Calpain may represent a novel molecular target for the treatment of PKC-associated diabetic vascular disease. (Arterioscler Thromb Vasc Biol. 2011;31:289-296.)
D iabetic patients have an increased risk of cardiovascular disease and inflammatory-type microvascular complications of target organs. Hyperglycemia, the hallmark of diabetes, initiates macro-and microvascular complications in part by inducing an endothelial inflammatory phenotype. 1 The ensuing endothelial dysfunction is considered causative of vascular and organ damage, and it is currently used as a prognostic indicator of diabetic complications. 2 Indeed, the dysfunctional endothelium becomes adhesive to circulating leukocytes, 3 a process implicated not only in vascular wall damage but also in organ tissue injury. 4 Hyperglycemia upregulates cell adhesion molecules expressed on the vascular endothelium, 5, 6 a process known to induce pathological leukocyte-endothelium interactions. 7 Accordingly, hyperglycemic expression of cell adhesion molecules expressed on the vascular endothelium has been extensively studied and mechanistically linked to macro-and microvascular complications in animal models of diabetes, as well as in diabetic humans.
Among the several adhesion molecules expressed by the inflamed endothelium, we focused on intercellular adhesion molecule-1 (ICAM-1) on the basis of recent evidence implicating ICAM-1 not only in atherogenesis 8 but also in diabetic organ complications. 9, 10 Hyperglycemic activation of protein kinase C (PKC) causes endothelial dysfunction with increased leukocyte-endothelium interactions. 11, 12 Inhibition of PKC attenuates leukocyte-endothelium interactions in experimental animal models of diabetes, as well as in human tissue exposed to elevated ambient glucose. 7, 13 PKC regulates ICAM-1 expression, 14, 15 but the pathways regulating ICAM-1 transcription by PKC have not been described. 16 PKC was originally discovered as a kinase cleaved by a calcium-dependent protease, now known as calpain. 17 Conversely, more recent in vitro studies have suggested that calpain can serve as a downstream target of PKC signaling. Thus, in platelets active calpain colocalizes with PKC at integrin signaling complexes. 18, 19 Studies in human lung cancer cells have also demonstrated that PKC increases calpain activity by phosphorylation. 20 Calpain is a cytosolic calcium-dependent cysteine protease. Two calpain isoforms, and m, are ubiquitously expressed and, thus, found in the vascular endothelium. 21 Calpain has been recently implicated in the endothelial dysfunction of acute and chronic hyperglycemia, 22, 23 as well as in the neurovascular dysfunction, 24 platelet hyperaggregability, 25 and cardiomyocyte apoptosis 26 of diabetes. Accordingly, we tested the novel hypothesis of a role for calpain in the endothelial dysfunction of hyperglycemic activation of PKC.
Materials and Methods
The Temple University Institutional Animal Care and Use Committee guidelines and the National Institutes of Health Policy on Humane Care and Use of Laboratory Animals were observed in this study. Male Sprague-Dawley rats 8 weeks of age were used (Ace Animals, Inc, Boyertown, Pa).
Insulin-Deficient Diabetes
Insulin deficiency with hyperglycemia, a condition similar to human type 1 diabetes, was induced by a single IP injection of 60 mg/kg streptozotocin (Sigma-Aldrich, St. Louis, Mo) dissolved in 0.9% saline. 27 Streptozotocin-injected rats (STZ-diabetes) developed and average blood glucose levels of 23.8Ϯ1.1 mmol/L (PϽ0.001 versus average values of 5.7Ϯ0.1 mmol/L found in nondiabetic control rats). Nondiabetic control rats and diabetic rats were randomly assigned to one of the following experimental groups: (1) 
Acute Hyperglycemia of the Peritoneal Cavity
To dissect the role of hyperglycemia alone in these studies, we used a well-established animal model of acute hyperglycemia of the peritoneal cavity, which is characterized by PKC-dependent endothelial dysfunction with increased leukocyte adhesion in the mesenteric microcirculation. 12 Rats were randomly divided into 4 groups: (1) control rats injected with 5 mmol/L D-glucose, (2) rats injected with 25 mmol/L L-glucose; (3) rats injected with 25 mmol/L D-glucose, and (4) rats injected with 25 mmol/L D-glucose ϩ30 nmol/L BIM-I. Saline and glucose were administered intraperitoneally 14 to 18 hours before study, as previously described. 28 L-Glucose was used to rule out nonspecific actions caused by osmolarity changes. For acute studies, BIM-I was administered as a single IP injection, 1 hour before intravital microscopy.
Inhibition of Calpain and Total PKC In Vivo
Total calpain inhibition was achieved with either of 2 different calpain inhibitors, ZLLal or PD150606. Total PKC inhibition was achieved with BIM-I. BIM-V was used as the inactive control for BiM-I.
Inhibition of PKC␤ in Rat Heart Microvascular Endothelial Cells
A 2-fold approach was used to dissect the role of PKC␤: (1) genetic inhibition using an adenovirus encoding a kinase-inactive rabbit PKC␤, 29 and (2) pharmacological inhibition using either the pan-PKC inhibitor BIM-I or the selective PKC␤ blocker LY379196, which blocks both PKC␤-I and PKC␤-II. 30 
Analyses of Calpain and PKC Activities
Analyses of calpain and PKC activities were performed using a fluorescent-based assay and a standard radioactive assay, respectively.
Quantification of Leukocyte-Endothelium Interactions
Leukocyte rolling and adhesion were studied by intravital microscopy of the mesenteric microcirculation. ICAM-1 expression levels were studied by fluorescent microscopy and Western blot analysis.
Data Analysis
All data are expressed as mean valuesϮSEM. Data were analyzed by ANOVA with a Newman-Keuls multiple comparison post test or with the Student t test using GraphPad Prism, version 5.0C for Macintosh (GraphPad Software, San Diego, Calif). Probability values less than 0.05 were considered statistically significant.
Supplemental Methods are available online at http://atvb.ahajournals.org.
Results

Insulin-Deficient Diabetes Increases PKC and Calpain Activities in the Vascular Mesentery
To study the relationship between PKC and calpain in STZ-diabetic rats, we first measured PKC and calpain activities in tissue extracts of vascularized sections of the mesentery, before and after pharmacological inhibition of calpain. STZ-diabetic rats exhibited an almost 2-fold increase in calpain activity (PϽ0.05 versus control, Figure 1A ) and a greater than 1.5-fold increase in PKC activity in the vascular mesentery (PϽ0.05 versus control, Figure 1B ). Treatment of STZ-diabetic rats with 27 g/kg of the calpain inhibitor ZLLal returned calpain activity to the control values found in nondiabetic rats (PϽ0.05, Figure 1A ), but failed to attenuate PKC activity ( Figure 1B ). Biochemical studies into the expression levels of the calpain isoform(s) found in the vascular wall revealed selective upregulation of -calpain but not m-calpain under our experimental conditions (Supplemental Figure I) . We next studied whether inhibition of PKC could prevent calpain activation in the intact microcirculation of STZdiabetic rats. For these studies, we coupled a fluorescent assay of calpain activity with in vivo microscopy of mesenteric postcapillary venules, which are microvessels comprised only by a layer of endothelial cells, a basement membrane, and a few scattered pericytes. 31 The advantage of this approach over the biochemical one described above is that it allows for simultaneous quantification and spatial localization of active calpains within the vascular endothelium of the observed microvasculature in vivo. In fact, the results obtained with the aortic and mesenteric tissue homogenates described in Figure 1 and Supplemental Figure I could in theory have been contaminated with vascular smooth muscle cells, which also upregulate PKC signaling in hyperglycemic conditions. 32 Fluorescent staining clearly demonstrated that the diabetic endothelium of postcapillary venules experiences increased calpain activity compared with control ( Figure 2B ). Quantification of the fluorescent staining revealed a 2-fold increase from control in endothelial-expressed calpain activity in STZ-diabetic rats, which was attenuated to control levels following pharmacological inhibition of calpain in vivo (PϽ0.05, Figure 2 , bar graph). These results are consistent with the biochemical analysis for calpain activity reported in Figure 1A . Two 30 nmol/L doses per day of the PKC inhibitor BIM-I significantly reduced endothelial calpain activity in STZ-diabetic rats (PϽ0.05, Figure 2 , bar graph). In contrast, treatment of rats with 2 doses per day of 30 nmol/L inactive PKC inhibitor BIM-V failed to attenuate calpain activity in STZ-diabetic rats (not significant), confirming the pharmacological specificity of PKC inhibitor used in these studies. Because calpain inhibition failed to prevent upregulation of PKC, these data indicate that calpain lies downstream of PKC in the vascular inflammation of diabetes. They also demonstrate that hyperglycemia with insulin deficiency upregulates calpain activity in the vascular endothelium and that this process is, in part, PKC dependent.
None of the above inhibitors changed blood glucose levels in diabetic rats (data not shown), ruling out the possibility that the vascular protective actions of calpain and PKC inhibition in vivo in our study were due to lowered glucose levels in the plasma.
The Role of PKC␤ in the Process of Calpain Activation
Among the several PKC isoforms, PKC␤ plays a widely accepted role in the microvascular complication of hyperglycemia. 11 Accordingly, we performed in vitro experiments to assess the role of PKC␤ in the process of endothelial calpain activation by hyperglycemia. Consistent with our in vivo results (Figure 2A ), rat heart microvascular endothelial cells exposed to elevated ambient glucose showed an approximately 1.5-fold increase in calpain activity over control ( Figure 3 ). Coincubation of rat heart microvascular endothelial cells with the calpain inhibitor ZLLal, the pan-PKC inhibitor BIM-I, or the selective PKC␤ blocker LY379196 prevented upregulation of calpain activity in the face of elevated glucose concentration ( Figure 3 ). Moreover, adenovirusmediated expression of a kinase-inactive dominant-negative PKC␤ also blocked calpain activation in response to elevated 
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ambient glucose, which further confirms the validity and specificity of the pharmacological results obtained in this study. Overall, these data agree with our in vivo observations reported in Figures 1 and 2 and they also demonstrate a role for the PKC␤ isoform in the process of endothelial calpain activation by elevated ambient glucose.
PKC/Calpain Upregulates Leukocyte-Endothelium Interactions
The postcapillary venules experiencing increased calpain activity ( Figure 2B ) are also the site of the microcirculation that regulates leukocyte-endothelium interactions, a process highly relevant to diabetic vascular complications. Accordingly, we measured leukocyte rolling ( Figure 4A ) and adhesion ( Figure 4B ) in mesenteric postcapillary venules by intravital microscopy. As shown in Figure 4 , the microcirculation of STZ-diabetic rats experiences increased adhesiveness to circulating leukocytes in postcapillary venules, a site where increased calpain activity was also observed (Figure 2 ). Specifically, we found evidence of 3-fold and 2.5-fold increases in leukocyte rolling and adhesion, respectively, in STZ-diabetic rats compared with nondiabetic rats (Figure 4 ). Both leukocyte rolling and adhesion were reduced following treatment of STZdiabetic rats with the PKC inhibitor BIM-I ( Figure 4) . In contrast, leukocyte rolling and adhesion remained elevated after administration of the inactive PKC inhibitor BIM-V to diabetic rats (not significant). Comparable results were obtained following inhibition of calpain activity with either of the 2 calpain inhibitors used in this study ( Figure  4 ). Administration of the calpain inhibitor ZLLal or PD150606 to diabetic rats each returned the values of leukocyte rolling and adhesion to near those found in nondiabetic control rats (Figure 4) . Thus, hyperglycemia with insulin deficiency induces abnormal leukocyte trafficking in the microcirculation through increased PKC/ calpain signaling.
PKC/Calpain Upregulates ICAM-1
The dysfunctional endothelium expresses ICAM-1, a cell adhesion molecule upregulated by PKC and implicated in diabetic vascular complications. 9, 15 We used Western blot analysis to study the impact of PKC/calpain signaling on ICAM-1 expression in the hyperglycemic, insulin-deficient vasculature of STZ diabetic rats ( Figure 5 ). Consistent with data in the literature, 14, 15 we found evidence of increased ICAM-1 expression in the aorta of STZ diabetic rats ( Figure 5 ), which was prevented by PKC inhibition in vivo ( Figure 5 ). Interestingly, inhibition of calpain activity also prevented upregulation of ICAM-1 expression in diabetic rats ( Figure 5 ), even in the face of increased PKC activity (Figure 1) . These results were confirmed by immunofluorescence of mesenteric postcapillary venules, which specifically demonstrated a calpain-dependent increase in ICAM-1 expression in the vascular endothelium of the diabetic microcirculation (Supplemental Figure II) . These data correlate with the antiadhesive effects of calpain inhibition on leukocyte-endothelium interactions reported above, and they are consistent with published studies indicating a role for PKC in the process of ICAM-1 transcription. 14, 15 The
Role of Hyperglycemia in the Process of PKC/Calpain Signaling
Hyperglycemia is the hallmark of insulin-deficient diabetes, and, on the basis of previous studies by our laboratory, 22 it is likely responsible for abnormal activation of endothelialexpressed calpains. Nonetheless, the possibility exists that the obvious loss of insulin signaling occurring in STZ-diabetic rats played a role in the process of endothelial calpain activation in this study. Accordingly, we studied the role of hyperglycemia alone in the process of PKC/calpain activation and actions using a well-established animal model of exper-imental hyperglycemia of the peritoneal cavity. The mesenteric microcirculation of nondiabetic control rats with preserved insulin signaling was exposed to 25 mmol/L D-glucose for 16 hours to acutely induce leukocyte-endothelium interactions. 28 Leukocyte adhesion and calpain activity were then measured simultaneously in mesenteric postcapillary vessels by intravital microscopy as reported above. The upper graph in Figure 6 shows that following a 16-hour exposure to elevated ambient glucose, the postcapillary venules of the mesentery experienced an Ϸ2.5-fold increase in calpain activity (PϽ0.05 versus control), as detected with the calpain substrate t-BOC-Leu-Met-CMAC (see also Figure 2 ). A nearly 3-fold increase in leukocyte adhesion (PϽ0.001) was also observed in the same postcapillary venules ( Figure 6 ). Administration of the PKC inhibitor BIM-I prevented glucose-induced calpain activation (PϽ0.05) and leukocyte adhesion (PϽ0.001). These results closely correlate with those found in STZ-diabetic rats (Figures 2 and 4) , thus confirming a causative role for hyperglycemia in the process of PKC-induced calpain activation and actions in the vascular endothelium. 
Discussion
The major findings of this study are that (1) under conditions of hyperglycemia with insulin deficiency, PKC activates -calpain, which leads to elevated expression levels of ICAM-1 and leukocyte-endothelium interactions; (2) pharmacological inhibition of calpain attenuates leukocyte-endothelium interactions and ICAM-1 expression even in the face of increased PKC activity; and (3) hyperglycemia, more than loss of insulin signaling, is primarily responsible for increased PKC/calpain signaling. Overall, these data demonstrate an emerging role for the calpain system in the inflammatory cascade of PKC and provide a new signaling pathway by which PKC regulates ICAM-1 expression in diabetic vascular disease.
PKC was originally recognized as a calpain substrate on the basis of biochemical studies that demonstrated calpain proteolysis of PKC. 17, 33 Accordingly, we had initially predicted that calpain would operate upstream of PKC. To the contrary, the results obtained in this study clearly show that in the hyperglycemic, insulin-deficient vasculature PKC regulates calpain activity, as demonstrated by the fact that inhibition of PKC attenuates calpain activation and not vice versa. This novel finding is supported by recent studies demonstrating a colocalization of PKC and calpain at the cell membrane on platelet activation. 18 In vitro studies of cancer cells have also provided direct evidence that PKC is responsible for calpain activation through phosphorylation, 20 a process known to increase activity of the protease. 34 With regard to endothelial function, one recent study in vitro has indirectly linked PKC and calpain in hyperglycemia. Thus, Wang et al 35 have suggested that the Na ϩ /H ϩ exchanger, a known PKC substrate 36 , is required for glucose-induced endothelial dysfunction via calpain. The data presented here support this working model in which primary activation of PKC results in elevated calpain activity and calpain-dependent endothelial dysfunction.
Based on cDNA cloning, the calpain family includes at least 15 isoforms, with the and m isoforms being ubiquitously expressed. 21 The names of the latter 2 isoforms describe the calcium concentrations required for their activation in vitro: micromolar for -calpain and millimolar for m-calpain. However, such calcium concentrations are rarely, if ever, found under physiological conditions. Thus, substantial controversy over the in vivo activation of calpain still exists. Biochemical studies have now demonstrated that posttranslational modifications of calpains by kinases result in their activation in the presence of reduced calcium levels. 37 Thus, PKC may indirectly activate calpain by increasing its calcium sensitivity. Additional studies need to be undertaken to identify the precise mechanism by which PKC activates calpain in diabetes, which will not only help understand the regulation of the PKC/calpain pathway but may also explain the molecular mechanisms responsible for preferential calpain isoform(s) activation.
PKC is known to be an important signaling molecule in diabetic endothelial dysfunction, and several PKC isoforms have been involved in the pathophysiology of vascular-driven diabetic complications. 11 There are at least 11 isoforms of PKC, and the activation of individual isoforms appears to be tissue specific. 11 The ␤ isoform has received much attention since it was first shown to be preferentially upregulated in diabetic vascular tissue. 38 The development of a specific inhibitor of this isoform 39 has allowed the assessment of diabetic vascular disturbances as a function of PKC␤. Our results in cultured endothelial cells provide novel evidence that calpain may function as an important downstream mediator of PKC␤ in diabetic endothelial dysfunction. They also may stimulate future research into the individual PKC isoforms implicated in the process of calpain activation and action in other relevant vascular tissues (eg, vascular smooth muscle cells) with the overall goal of understanding how activation of PKC/calpain signaling impacts the homeostasis of the entire vascular wall under physiological and pathophysiologic conditions.
A large amount of data in the literature has confirmed the association between deregulated PKC activity and vascular dysfunction, including but not limited to increased leukocyteendothelium interactions. 11, 16 Our laboratory was the first to report that calpain is uniquely activated in the endothelial dysfunction associated with acute hyperglycemia 22 and obesity. 23 In line with our observations, others have now documented a role for calpain in the neurovascular dysfunction and platelet hyperaggregability of type 2 diabetes 24, 25 in the apoptosis of hyperglycemic cardiomyocytes, 26 and in hyperlipidemic endothelial dysfunction. 40 The present study provides novel evidence that calpain also serves as an important downstream signaling mediator of PKC in hyperglycemia with insulin deficiency. At the functional level, pharmacological inhibition of calpain activity abrogated leukocyte-endothelium interactions and ICAM-1 expression in the hyperglycemic vasculature, even in the face of increased PKC activity. These findings are in line with previous evidence demonstrating hyperglycemic expression of ICAM-1 through either PKC 7 or calpain. 22 Relevant to vascular disease, upregulated ICAM-1 expression from exposure to the hyperglycemic environment is associated with enhanced atheroma formation 8 and organ tissue damage. 10 Thus, targeting calpain and PKC together in diabetes may afford enhanced vascular protection by reducing the pathogenic expression of ICAM-1. Albeit both conventional and atypical PKC have been involved in regulation of ICAM-1 expression, 14, 15 the pathways responsible for regulating ICAM-1 transcription during highglucose concentration remains largely unknown. Our data demonstrate the mechanistic role of calpain in the process of endothelial ICAM-1 upregulation in the hyperglycemic vasculature experiencing also increased PKC activity, thus providing a novel signaling pathways by which PKC upregulates inflammatory signals in hyperglycemia.
Hyperglycemia is only one of the many metabolic alterations of diabetes. Nonetheless, hyperglycemia remains the diabetic disturbance most largely associated with vascular complications, as demonstrated by the results of the Diabetes Control and Complications Trial. 41 Activation of PKC via the de novo production of diacylglycerol is one of the most accepted mechanisms by which hyperglycemia induces endothelial dysfunction and vascular inflammation. The experimental results obtained in our rat model of acute hyperglycemia of the peritoneal cavity further confirm the role of hyperglycemia in the process of PKC activation in the insulin deficient cardiovascular system, and they also uncover a role for calpain in the endothelial dysfunction resulting from acute hyperglycemic activation of PKC. Finally, our study did not explore how sex differences affect the PKC/calpain signaling cascade, because all results were obtained in male mice. Given the well-established role that sex hormones play both in the regulation of metabolic parameters and in the progression of cardiovascular disease, further studies are clearly needed to understand how sex-linked difference regulate endothelial PKC/calpain signaling under pathophysiological conditions.
In summary, we have shown that activation of PKC in hyperglycemia with insulin deficiency increases endothelial calpain activity, with a preferential activation of the -calpain isoform. The pathophysiologic implication of this enhanced calpain activity is that there is ICAM-1 upregulation with increased leukocyte trafficking in the microcirculation. 
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